‘People are complex.’ Meet 3 generations of a Georgia family.
Leading up to the state’s U.S. Senate runoffs, the Gamel family shared their thoughts on voting and the current political climate. — NYT: Top Stories
Leading up to the state’s U.S. Senate runoffs, the Gamel family shared their thoughts on voting and the current political climate. — NYT: Top Stories
Shia LaBeouf’s co-star Vanessa Kirby has issued a statement about abuse nearly a month after a lawsuit was filed against the actor claiming he previously abused women. — FOX News
Tanya Roberts, the one-time Bond girl, and “That ’70s Show” actress died on Monday following an incorrect statement from her representative that she had died one day prior. — FOX News
The small Arab nation of Qatar has been under a blockade by air, land, and sea since 2017, when neighboring nations accused it of supporting terrorism and aligning too closely with Iran. — NYT: Top Stories
PARAMUS, N.J.–(BUSINESS WIRE)–Movado Group, Inc. [NYSE: MOV] announced today that the Company will be presenting at the 23rd Annual ICR Conference on Tuesday, January 12, 2021 at 4:30 pm Eastern Time. Efraim Grinberg, Chairman and Chief Executive Officer, and Sallie DeMarsilis, Executive
The first step to addressing the country’s housing affordability problem is to repeal the Faircloth Amendment. With Covid-19 still upsetting the economy, eviction moratoriums are still in effect, but will expire. As a result, the housing concerns are real. A “crushing” housing
Is it wiser to hold back the second doses everyone will need, or to give as many people as possible a shot now? There are concerns due to a supply constraint. Only Pfizer and Moderna vaccines are authorized, even though policymakers had
U.S. officials want the WikiLeaks founder, Julian Assange, to face charges of violating the Espionage Act. But a judge in London ruled that he was at extreme risk of suicide. — NYT: Top Stories
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients